nodes	percent_of_prediction	percent_of_DWPC	metapath
Etonogestrel—CYP3A4—Cytarabine—lymphatic system cancer	0.0678	0.318	CbGbCtD
Etonogestrel—CYP3A4—Teniposide—lymphatic system cancer	0.0667	0.313	CbGbCtD
Etonogestrel—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0467	0.219	CbGbCtD
Etonogestrel—CYP3A4—Vincristine—lymphatic system cancer	0.0321	0.151	CbGbCtD
Etonogestrel—Anorexia—Fludarabine—lymphatic system cancer	0.00252	0.00321	CcSEcCtD
Etonogestrel—Weight increased—Mitoxantrone—lymphatic system cancer	0.00252	0.0032	CcSEcCtD
Etonogestrel—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00251	0.00319	CcSEcCtD
Etonogestrel—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00249	0.00316	CcSEcCtD
Etonogestrel—Feeling abnormal—Teniposide—lymphatic system cancer	0.00248	0.00316	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00246	0.00313	CcSEcCtD
Etonogestrel—Nausea—Mechlorethamine—lymphatic system cancer	0.00243	0.00309	CcSEcCtD
Etonogestrel—Alopecia—Bleomycin—lymphatic system cancer	0.00241	0.00307	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00241	0.00307	CcSEcCtD
Etonogestrel—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.0024	0.00305	CcSEcCtD
Etonogestrel—Haemoglobin—Carmustine—lymphatic system cancer	0.0024	0.00305	CcSEcCtD
Etonogestrel—Urticaria—Teniposide—lymphatic system cancer	0.00239	0.00304	CcSEcCtD
Etonogestrel—Herpes simplex—Methotrexate—lymphatic system cancer	0.00239	0.00303	CcSEcCtD
Etonogestrel—Haemorrhage—Carmustine—lymphatic system cancer	0.00238	0.00303	CcSEcCtD
Etonogestrel—Abdominal pain—Teniposide—lymphatic system cancer	0.00238	0.00303	CcSEcCtD
Etonogestrel—Body temperature increased—Teniposide—lymphatic system cancer	0.00238	0.00303	CcSEcCtD
Etonogestrel—Erythema—Bleomycin—lymphatic system cancer	0.00238	0.00302	CcSEcCtD
Etonogestrel—Paraesthesia—Fludarabine—lymphatic system cancer	0.00238	0.00302	CcSEcCtD
Etonogestrel—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00237	0.00302	CcSEcCtD
Etonogestrel—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00234	0.00298	CcSEcCtD
Etonogestrel—Dyspepsia—Fludarabine—lymphatic system cancer	0.00233	0.00296	CcSEcCtD
Etonogestrel—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00232	0.00295	CcSEcCtD
Etonogestrel—Decreased appetite—Fludarabine—lymphatic system cancer	0.0023	0.00293	CcSEcCtD
Etonogestrel—Visual impairment—Carmustine—lymphatic system cancer	0.0023	0.00292	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00229	0.00291	CcSEcCtD
Etonogestrel—Fatigue—Fludarabine—lymphatic system cancer	0.00228	0.0029	CcSEcCtD
Etonogestrel—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00226	0.00288	CcSEcCtD
Etonogestrel—Constipation—Fludarabine—lymphatic system cancer	0.00226	0.00288	CcSEcCtD
Etonogestrel—Pain—Fludarabine—lymphatic system cancer	0.00226	0.00288	CcSEcCtD
Etonogestrel—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00225	0.00286	CcSEcCtD
Etonogestrel—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00224	0.00284	CcSEcCtD
Etonogestrel—Urethral disorder—Vincristine—lymphatic system cancer	0.00223	0.00284	CcSEcCtD
Etonogestrel—Eye disorder—Carmustine—lymphatic system cancer	0.00223	0.00283	CcSEcCtD
Etonogestrel—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00223	0.00283	CcSEcCtD
Etonogestrel—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00222	0.00283	CcSEcCtD
Etonogestrel—Hypersensitivity—Teniposide—lymphatic system cancer	0.00222	0.00282	CcSEcCtD
Etonogestrel—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00222	0.00282	CcSEcCtD
Etonogestrel—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00221	0.00281	CcSEcCtD
Etonogestrel—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.0022	0.0028	CcSEcCtD
Etonogestrel—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.0022	0.0028	CcSEcCtD
Etonogestrel—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00218	0.00277	CcSEcCtD
Etonogestrel—Asthenia—Teniposide—lymphatic system cancer	0.00216	0.00275	CcSEcCtD
Etonogestrel—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00215	0.00273	CcSEcCtD
Etonogestrel—Malaise—Bleomycin—lymphatic system cancer	0.00214	0.00273	CcSEcCtD
Etonogestrel—Pruritus—Teniposide—lymphatic system cancer	0.00213	0.00271	CcSEcCtD
Etonogestrel—Cystitis—Methotrexate—lymphatic system cancer	0.00212	0.0027	CcSEcCtD
Etonogestrel—Alopecia—Carmustine—lymphatic system cancer	0.00211	0.00268	CcSEcCtD
Etonogestrel—Body temperature increased—Fludarabine—lymphatic system cancer	0.00209	0.00266	CcSEcCtD
Etonogestrel—Mental disorder—Carmustine—lymphatic system cancer	0.00209	0.00266	CcSEcCtD
Etonogestrel—Vaginal infection—Methotrexate—lymphatic system cancer	0.00208	0.00264	CcSEcCtD
Etonogestrel—Erythema—Carmustine—lymphatic system cancer	0.00208	0.00264	CcSEcCtD
Etonogestrel—Malnutrition—Carmustine—lymphatic system cancer	0.00208	0.00264	CcSEcCtD
Etonogestrel—Cough—Bleomycin—lymphatic system cancer	0.00208	0.00264	CcSEcCtD
Etonogestrel—Angiopathy—Vincristine—lymphatic system cancer	0.00207	0.00263	CcSEcCtD
Etonogestrel—Diarrhoea—Teniposide—lymphatic system cancer	0.00206	0.00262	CcSEcCtD
Etonogestrel—Myalgia—Bleomycin—lymphatic system cancer	0.00202	0.00257	CcSEcCtD
Etonogestrel—Alopecia—Vincristine—lymphatic system cancer	0.00201	0.00256	CcSEcCtD
Etonogestrel—Back pain—Carmustine—lymphatic system cancer	0.00201	0.00255	CcSEcCtD
Etonogestrel—Discomfort—Bleomycin—lymphatic system cancer	0.002	0.00254	CcSEcCtD
Etonogestrel—Mental disorder—Vincristine—lymphatic system cancer	0.00199	0.00254	CcSEcCtD
Etonogestrel—Neoplasm—Methotrexate—lymphatic system cancer	0.00199	0.00253	CcSEcCtD
Etonogestrel—Bladder pain—Methotrexate—lymphatic system cancer	0.00199	0.00253	CcSEcCtD
Etonogestrel—Alopecia—Mitoxantrone—lymphatic system cancer	0.00196	0.00249	CcSEcCtD
Etonogestrel—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00195	0.00248	CcSEcCtD
Etonogestrel—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00194	0.00247	CcSEcCtD
Etonogestrel—Oedema—Bleomycin—lymphatic system cancer	0.00194	0.00247	CcSEcCtD
Etonogestrel—Erythema—Mitoxantrone—lymphatic system cancer	0.00193	0.00245	CcSEcCtD
Etonogestrel—Infection—Bleomycin—lymphatic system cancer	0.00193	0.00245	CcSEcCtD
Etonogestrel—Back pain—Vincristine—lymphatic system cancer	0.00192	0.00244	CcSEcCtD
Etonogestrel—Vomiting—Teniposide—lymphatic system cancer	0.00192	0.00243	CcSEcCtD
Etonogestrel—Asthenia—Fludarabine—lymphatic system cancer	0.0019	0.00241	CcSEcCtD
Etonogestrel—Rash—Teniposide—lymphatic system cancer	0.0019	0.00241	CcSEcCtD
Etonogestrel—Dermatitis—Teniposide—lymphatic system cancer	0.0019	0.00241	CcSEcCtD
Etonogestrel—Headache—Teniposide—lymphatic system cancer	0.00189	0.0024	CcSEcCtD
Etonogestrel—Pruritus—Fludarabine—lymphatic system cancer	0.00187	0.00238	CcSEcCtD
Etonogestrel—Back pain—Mitoxantrone—lymphatic system cancer	0.00187	0.00237	CcSEcCtD
Etonogestrel—Anorexia—Bleomycin—lymphatic system cancer	0.00185	0.00235	CcSEcCtD
Etonogestrel—Diarrhoea—Fludarabine—lymphatic system cancer	0.00181	0.0023	CcSEcCtD
Etonogestrel—Convulsion—Carmustine—lymphatic system cancer	0.0018	0.00229	CcSEcCtD
Etonogestrel—Hypertension—Carmustine—lymphatic system cancer	0.00179	0.00228	CcSEcCtD
Etonogestrel—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00179	0.00228	CcSEcCtD
Etonogestrel—Nausea—Teniposide—lymphatic system cancer	0.00179	0.00227	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00177	0.00225	CcSEcCtD
Etonogestrel—Myalgia—Carmustine—lymphatic system cancer	0.00177	0.00225	CcSEcCtD
Etonogestrel—Anxiety—Carmustine—lymphatic system cancer	0.00176	0.00224	CcSEcCtD
Etonogestrel—Paraesthesia—Bleomycin—lymphatic system cancer	0.00174	0.00222	CcSEcCtD
Etonogestrel—Malaise—Mitoxantrone—lymphatic system cancer	0.00174	0.00221	CcSEcCtD
Etonogestrel—Convulsion—Vincristine—lymphatic system cancer	0.00172	0.00218	CcSEcCtD
Etonogestrel—Hypertension—Vincristine—lymphatic system cancer	0.00171	0.00217	CcSEcCtD
Etonogestrel—Oedema—Carmustine—lymphatic system cancer	0.00169	0.00215	CcSEcCtD
Etonogestrel—Decreased appetite—Bleomycin—lymphatic system cancer	0.00169	0.00214	CcSEcCtD
Etonogestrel—Myalgia—Vincristine—lymphatic system cancer	0.00169	0.00214	CcSEcCtD
Etonogestrel—Visual disturbance—Methotrexate—lymphatic system cancer	0.00168	0.00214	CcSEcCtD
Etonogestrel—Cough—Mitoxantrone—lymphatic system cancer	0.00168	0.00214	CcSEcCtD
Etonogestrel—Infection—Carmustine—lymphatic system cancer	0.00168	0.00214	CcSEcCtD
Etonogestrel—Vomiting—Fludarabine—lymphatic system cancer	0.00168	0.00214	CcSEcCtD
Etonogestrel—Convulsion—Mitoxantrone—lymphatic system cancer	0.00167	0.00213	CcSEcCtD
Etonogestrel—Rash—Fludarabine—lymphatic system cancer	0.00167	0.00212	CcSEcCtD
Etonogestrel—Dermatitis—Fludarabine—lymphatic system cancer	0.00167	0.00212	CcSEcCtD
Etonogestrel—Hypertension—Mitoxantrone—lymphatic system cancer	0.00167	0.00212	CcSEcCtD
Etonogestrel—Pain—Bleomycin—lymphatic system cancer	0.00166	0.00211	CcSEcCtD
Etonogestrel—Headache—Fludarabine—lymphatic system cancer	0.00166	0.00211	CcSEcCtD
Etonogestrel—Myalgia—Mitoxantrone—lymphatic system cancer	0.00164	0.00209	CcSEcCtD
Etonogestrel—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00164	0.00209	CcSEcCtD
Etonogestrel—Anxiety—Mitoxantrone—lymphatic system cancer	0.00164	0.00208	CcSEcCtD
Etonogestrel—Discomfort—Mitoxantrone—lymphatic system cancer	0.00162	0.00206	CcSEcCtD
Etonogestrel—Oedema—Vincristine—lymphatic system cancer	0.00162	0.00206	CcSEcCtD
Etonogestrel—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00162	0.00206	CcSEcCtD
Etonogestrel—Anorexia—Carmustine—lymphatic system cancer	0.00161	0.00205	CcSEcCtD
Etonogestrel—Infection—Vincristine—lymphatic system cancer	0.00161	0.00204	CcSEcCtD
Etonogestrel—Feeling abnormal—Bleomycin—lymphatic system cancer	0.0016	0.00203	CcSEcCtD
Etonogestrel—Nervous system disorder—Vincristine—lymphatic system cancer	0.00159	0.00202	CcSEcCtD
Etonogestrel—Oedema—Mitoxantrone—lymphatic system cancer	0.00158	0.002	CcSEcCtD
Etonogestrel—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00158	0.002	CcSEcCtD
Etonogestrel—Nausea—Fludarabine—lymphatic system cancer	0.00157	0.002	CcSEcCtD
Etonogestrel—Infection—Mitoxantrone—lymphatic system cancer	0.00156	0.00199	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00154	0.00196	CcSEcCtD
Etonogestrel—Urticaria—Bleomycin—lymphatic system cancer	0.00154	0.00196	CcSEcCtD
Etonogestrel—Anorexia—Vincristine—lymphatic system cancer	0.00154	0.00196	CcSEcCtD
Etonogestrel—Body temperature increased—Bleomycin—lymphatic system cancer	0.00153	0.00195	CcSEcCtD
Etonogestrel—Insomnia—Carmustine—lymphatic system cancer	0.00153	0.00195	CcSEcCtD
Etonogestrel—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00153	0.00194	CcSEcCtD
Etonogestrel—Irritability—Methotrexate—lymphatic system cancer	0.00152	0.00194	CcSEcCtD
Etonogestrel—Paraesthesia—Carmustine—lymphatic system cancer	0.00152	0.00193	CcSEcCtD
Etonogestrel—Mood swings—Methotrexate—lymphatic system cancer	0.00151	0.00192	CcSEcCtD
Etonogestrel—Somnolence—Carmustine—lymphatic system cancer	0.00151	0.00191	CcSEcCtD
Etonogestrel—Anorexia—Mitoxantrone—lymphatic system cancer	0.0015	0.00191	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00147	0.00187	CcSEcCtD
Etonogestrel—Decreased appetite—Carmustine—lymphatic system cancer	0.00147	0.00187	CcSEcCtD
Etonogestrel—Insomnia—Vincristine—lymphatic system cancer	0.00146	0.00186	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00146	0.00186	CcSEcCtD
Etonogestrel—Paraesthesia—Vincristine—lymphatic system cancer	0.00145	0.00185	CcSEcCtD
Etonogestrel—Pain—Carmustine—lymphatic system cancer	0.00145	0.00184	CcSEcCtD
Etonogestrel—Constipation—Carmustine—lymphatic system cancer	0.00145	0.00184	CcSEcCtD
Etonogestrel—Breast disorder—Methotrexate—lymphatic system cancer	0.00144	0.00183	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00143	0.00182	CcSEcCtD
Etonogestrel—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00143	0.00182	CcSEcCtD
Etonogestrel—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00141	0.0018	CcSEcCtD
Etonogestrel—Decreased appetite—Vincristine—lymphatic system cancer	0.00141	0.00179	CcSEcCtD
Etonogestrel—Somnolence—Mitoxantrone—lymphatic system cancer	0.0014	0.00178	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0014	0.00178	CcSEcCtD
Etonogestrel—Feeling abnormal—Carmustine—lymphatic system cancer	0.0014	0.00177	CcSEcCtD
Etonogestrel—Fatigue—Vincristine—lymphatic system cancer	0.00139	0.00177	CcSEcCtD
Etonogestrel—Asthenia—Bleomycin—lymphatic system cancer	0.00139	0.00177	CcSEcCtD
Etonogestrel—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00139	0.00176	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00139	0.00176	CcSEcCtD
Etonogestrel—Constipation—Vincristine—lymphatic system cancer	0.00138	0.00176	CcSEcCtD
Etonogestrel—Pain—Vincristine—lymphatic system cancer	0.00138	0.00176	CcSEcCtD
Etonogestrel—Asthma—Methotrexate—lymphatic system cancer	0.00138	0.00175	CcSEcCtD
Etonogestrel—Pruritus—Bleomycin—lymphatic system cancer	0.00137	0.00175	CcSEcCtD
Etonogestrel—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00137	0.00174	CcSEcCtD
Etonogestrel—Fatigue—Mitoxantrone—lymphatic system cancer	0.00136	0.00173	CcSEcCtD
Etonogestrel—Pain—Mitoxantrone—lymphatic system cancer	0.00135	0.00171	CcSEcCtD
Etonogestrel—Constipation—Mitoxantrone—lymphatic system cancer	0.00135	0.00171	CcSEcCtD
Etonogestrel—Abdominal pain—Carmustine—lymphatic system cancer	0.00134	0.0017	CcSEcCtD
Etonogestrel—Body temperature increased—Carmustine—lymphatic system cancer	0.00134	0.0017	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00132	0.00168	CcSEcCtD
Etonogestrel—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.0013	0.00165	CcSEcCtD
Etonogestrel—Dysuria—Methotrexate—lymphatic system cancer	0.00129	0.00164	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00129	0.00164	CcSEcCtD
Etonogestrel—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00128	0.00163	CcSEcCtD
Etonogestrel—Abdominal pain—Vincristine—lymphatic system cancer	0.00128	0.00163	CcSEcCtD
Etonogestrel—Body temperature increased—Vincristine—lymphatic system cancer	0.00128	0.00163	CcSEcCtD
Etonogestrel—Urticaria—Mitoxantrone—lymphatic system cancer	0.00125	0.00159	CcSEcCtD
Etonogestrel—Hypersensitivity—Carmustine—lymphatic system cancer	0.00125	0.00159	CcSEcCtD
Etonogestrel—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00125	0.00158	CcSEcCtD
Etonogestrel—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00125	0.00158	CcSEcCtD
Etonogestrel—Vomiting—Bleomycin—lymphatic system cancer	0.00123	0.00157	CcSEcCtD
Etonogestrel—Infestation NOS—Methotrexate—lymphatic system cancer	0.00123	0.00156	CcSEcCtD
Etonogestrel—Infestation—Methotrexate—lymphatic system cancer	0.00123	0.00156	CcSEcCtD
Etonogestrel—Depression—Methotrexate—lymphatic system cancer	0.00123	0.00156	CcSEcCtD
Etonogestrel—Rash—Bleomycin—lymphatic system cancer	0.00122	0.00156	CcSEcCtD
Etonogestrel—Dermatitis—Bleomycin—lymphatic system cancer	0.00122	0.00155	CcSEcCtD
Etonogestrel—Asthenia—Carmustine—lymphatic system cancer	0.00122	0.00155	CcSEcCtD
Etonogestrel—Hypersensitivity—Vincristine—lymphatic system cancer	0.00119	0.00151	CcSEcCtD
Etonogestrel—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00116	0.00148	CcSEcCtD
Etonogestrel—Asthenia—Vincristine—lymphatic system cancer	0.00116	0.00148	CcSEcCtD
Etonogestrel—Diarrhoea—Carmustine—lymphatic system cancer	0.00116	0.00147	CcSEcCtD
Etonogestrel—Nausea—Bleomycin—lymphatic system cancer	0.00115	0.00147	CcSEcCtD
Etonogestrel—Asthenia—Mitoxantrone—lymphatic system cancer	0.00113	0.00144	CcSEcCtD
Etonogestrel—Dizziness—Carmustine—lymphatic system cancer	0.00112	0.00142	CcSEcCtD
Etonogestrel—Haemoglobin—Methotrexate—lymphatic system cancer	0.00111	0.00141	CcSEcCtD
Etonogestrel—Diarrhoea—Vincristine—lymphatic system cancer	0.00111	0.00141	CcSEcCtD
Etonogestrel—Haemorrhage—Methotrexate—lymphatic system cancer	0.0011	0.0014	CcSEcCtD
Etonogestrel—Pharyngitis—Methotrexate—lymphatic system cancer	0.0011	0.00139	CcSEcCtD
Etonogestrel—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00109	0.00139	CcSEcCtD
Etonogestrel—Urethral disorder—Methotrexate—lymphatic system cancer	0.00108	0.00138	CcSEcCtD
Etonogestrel—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00108	0.00137	CcSEcCtD
Etonogestrel—Vomiting—Carmustine—lymphatic system cancer	0.00108	0.00137	CcSEcCtD
Etonogestrel—Dizziness—Vincristine—lymphatic system cancer	0.00107	0.00136	CcSEcCtD
Etonogestrel—Rash—Carmustine—lymphatic system cancer	0.00107	0.00136	CcSEcCtD
Etonogestrel—Dermatitis—Carmustine—lymphatic system cancer	0.00107	0.00136	CcSEcCtD
Etonogestrel—Visual impairment—Methotrexate—lymphatic system cancer	0.00106	0.00135	CcSEcCtD
Etonogestrel—Headache—Carmustine—lymphatic system cancer	0.00106	0.00135	CcSEcCtD
Etonogestrel—Eye disorder—Methotrexate—lymphatic system cancer	0.00103	0.00131	CcSEcCtD
Etonogestrel—Vomiting—Vincristine—lymphatic system cancer	0.00103	0.00131	CcSEcCtD
Etonogestrel—Rash—Vincristine—lymphatic system cancer	0.00102	0.0013	CcSEcCtD
Etonogestrel—Dermatitis—Vincristine—lymphatic system cancer	0.00102	0.0013	CcSEcCtD
Etonogestrel—Headache—Vincristine—lymphatic system cancer	0.00101	0.00129	CcSEcCtD
Etonogestrel—Nausea—Carmustine—lymphatic system cancer	0.00101	0.00128	CcSEcCtD
Etonogestrel—Angiopathy—Methotrexate—lymphatic system cancer	0.001	0.00127	CcSEcCtD
Etonogestrel—Vomiting—Mitoxantrone—lymphatic system cancer	0.001	0.00127	CcSEcCtD
Etonogestrel—Immune system disorder—Methotrexate—lymphatic system cancer	0.000998	0.00127	CcSEcCtD
Etonogestrel—Rash—Mitoxantrone—lymphatic system cancer	0.000993	0.00126	CcSEcCtD
Etonogestrel—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000992	0.00126	CcSEcCtD
Etonogestrel—Headache—Mitoxantrone—lymphatic system cancer	0.000987	0.00125	CcSEcCtD
Etonogestrel—Alopecia—Methotrexate—lymphatic system cancer	0.000976	0.00124	CcSEcCtD
Etonogestrel—Mental disorder—Methotrexate—lymphatic system cancer	0.000968	0.00123	CcSEcCtD
Etonogestrel—Erythema—Methotrexate—lymphatic system cancer	0.000962	0.00122	CcSEcCtD
Etonogestrel—Malnutrition—Methotrexate—lymphatic system cancer	0.000962	0.00122	CcSEcCtD
Etonogestrel—Nausea—Vincristine—lymphatic system cancer	0.000961	0.00122	CcSEcCtD
Etonogestrel—Nausea—Mitoxantrone—lymphatic system cancer	0.000936	0.00119	CcSEcCtD
Etonogestrel—Back pain—Methotrexate—lymphatic system cancer	0.00093	0.00118	CcSEcCtD
Etonogestrel—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000892	0.00113	CcSEcCtD
Etonogestrel—Malaise—Methotrexate—lymphatic system cancer	0.000867	0.0011	CcSEcCtD
Etonogestrel—Cough—Methotrexate—lymphatic system cancer	0.000839	0.00107	CcSEcCtD
Etonogestrel—Convulsion—Methotrexate—lymphatic system cancer	0.000833	0.00106	CcSEcCtD
Etonogestrel—Myalgia—Methotrexate—lymphatic system cancer	0.000819	0.00104	CcSEcCtD
Etonogestrel—Arthralgia—Methotrexate—lymphatic system cancer	0.000819	0.00104	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000813	0.00103	CcSEcCtD
Etonogestrel—Discomfort—Methotrexate—lymphatic system cancer	0.000809	0.00103	CcSEcCtD
Etonogestrel—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000785	0.000998	CcSEcCtD
Etonogestrel—Infection—Methotrexate—lymphatic system cancer	0.00078	0.000991	CcSEcCtD
Etonogestrel—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00077	0.000978	CcSEcCtD
Etonogestrel—Skin disorder—Methotrexate—lymphatic system cancer	0.000762	0.000969	CcSEcCtD
Etonogestrel—Anorexia—Methotrexate—lymphatic system cancer	0.000748	0.000951	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000715	0.000909	CcSEcCtD
Etonogestrel—Insomnia—Methotrexate—lymphatic system cancer	0.00071	0.000902	CcSEcCtD
Etonogestrel—Paraesthesia—Methotrexate—lymphatic system cancer	0.000705	0.000896	CcSEcCtD
Etonogestrel—Somnolence—Methotrexate—lymphatic system cancer	0.000698	0.000887	CcSEcCtD
Etonogestrel—Dyspepsia—Methotrexate—lymphatic system cancer	0.000691	0.000878	CcSEcCtD
Etonogestrel—Decreased appetite—Methotrexate—lymphatic system cancer	0.000682	0.000867	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000677	0.000861	CcSEcCtD
Etonogestrel—Fatigue—Methotrexate—lymphatic system cancer	0.000677	0.00086	CcSEcCtD
Etonogestrel—Pain—Methotrexate—lymphatic system cancer	0.000671	0.000853	CcSEcCtD
Etonogestrel—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000647	0.000822	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000642	0.000816	CcSEcCtD
Etonogestrel—Urticaria—Methotrexate—lymphatic system cancer	0.000623	0.000793	CcSEcCtD
Etonogestrel—Abdominal pain—Methotrexate—lymphatic system cancer	0.00062	0.000789	CcSEcCtD
Etonogestrel—Body temperature increased—Methotrexate—lymphatic system cancer	0.00062	0.000789	CcSEcCtD
Etonogestrel—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000578	0.000735	CcSEcCtD
Etonogestrel—Asthenia—Methotrexate—lymphatic system cancer	0.000563	0.000716	CcSEcCtD
Etonogestrel—Pruritus—Methotrexate—lymphatic system cancer	0.000555	0.000706	CcSEcCtD
Etonogestrel—Diarrhoea—Methotrexate—lymphatic system cancer	0.000537	0.000683	CcSEcCtD
Etonogestrel—Dizziness—Methotrexate—lymphatic system cancer	0.000519	0.00066	CcSEcCtD
Etonogestrel—Vomiting—Methotrexate—lymphatic system cancer	0.000499	0.000634	CcSEcCtD
Etonogestrel—Rash—Methotrexate—lymphatic system cancer	0.000495	0.000629	CcSEcCtD
Etonogestrel—Dermatitis—Methotrexate—lymphatic system cancer	0.000494	0.000628	CcSEcCtD
Etonogestrel—Headache—Methotrexate—lymphatic system cancer	0.000492	0.000625	CcSEcCtD
Etonogestrel—Nausea—Methotrexate—lymphatic system cancer	0.000466	0.000593	CcSEcCtD
